ClinicalTrials.gg
CompletedNCT04217993Updated Apr 20, 2023

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

A Phase 2 interventional study of Jaktinib hydrochloride tablets in Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis(Post-PV MF) and Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-20.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing jaktinib in Primary Myelofibrosis — 4 open to participants now, 4 under way, none of them phase 3. jaktinib · Primary Myelofibrosis.

Enrollment
4th of 10
51 · median 37
Started
2020
the only one that year
Phase 2
4 of 10
1 open now
Registered
2nd of 10
by date
Lead sponsor
7 of 10
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 10 studies testing jaktinib in Primary Myelofibrosis, this one is the 4th largest by enrollment, is the only one that started in 2020, is one of 4 in phase 2, and was the 2nd registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

4 of the 10 studies testing jaktinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About jaktinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing jaktinib in Primary Myelofibrosis, or all of them as a file.
02

Study summary

This phase IIB, open-label, multicenter study evaluated the efficacy and safety of oral Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib. The experiment is divided into two parts: dose exploration and extended research.

Read the detailed description

dose exploration: It is planned to enroll about 6 subjects. According to the baseline value of platelet count at the time of enrollment, different doses (100mg Qd or 150mg Qd or 200mg Qd or 100mg Bid) of Jaktinib Hydrochloride Tablets will be Treated. The trial is in progress Adjust the dose according to relevant laboratory indicators. When at least one subject has a spleen volume reduction of ≥35% from the baseline, the sponsor and the investigator will jointly decide whether to enter the extended study part.

Extended research: It is planned to enroll about 43 subjects, and the initial dosage of Jaktinib Hydrochloride Tablets is planned to be 100mg Bid.

03

Conditions studied

  • Primary Myelofibrosis (PMF)
  • Post-polycythemia Vera Myelofibrosis(Post-PV MF)
  • Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-75 years old (including the threshold value), gender is not limited;
  2. Subjects diagnosed with Primary Myelofibrosis according to World Health Organization (WHO) criteria (2016 version), or diagnosed with Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis according to International Working Group Myeloproliferative Neoplasms Research and Treatment(IWG-MRT) standard. Both Janus Kinase 2(JAK2)mutation and JAK2 wild can be enrolled;
  3. According to Dynamic International Prognostic Scoring System(DIPSS) , Subjects with intermediate-risk-2 or high-risk myelofibrosis were assessed, Subjects with intermediate-risk-1 myelofibrosis with hepatosplenomegaly and no response to existing treatment and requiring treatment can also be enrolled;
  4. Subjects who have received or are receiving Ruxolitinib, and:Ruxolitinib treatment time is not less than 28 days; Red blood cell transfusion is still needed during treatment with Ruxolitinib; or Ruxolitinib dose (including starting dose and adjusted dose)\<20mg bid,And must meet at least one of the following:Level 3 or higher count reduction or Level 3 or higher anemia or Level 3 or higher hematoma/bleeding;
  5. > 24 weeks;
  6. (ECOG) Performance Score (PS) of 0, 1 or 2;
  7. Splenomegaly: palpation of the splenic margin to or above the subcostal at least 5cm;
  8. Acceptable laboratory assessments obtained within 14 days prior to enrollment:

    • (ANC)>0.75 x 10\^9/L, blood platelet count>100 x 10\^9/L;
    • Peripheral blood blast count \< 10%;
    • (AST) and alanine transaminase (ALT)≤3 x the (ULN); Subjects with liver function impairment due to severe extramedullary haematopoiesis or iron removal therapy within 60 days prior to screening, AST and ALT≤5 x ULN; Direct ≤2.0 x ULN;
    • Calculated of≥45 mL/min;
  9. Meet the requirements of the Ethics Committee, voluntarily sign an form;
  10. Ability to follow research and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any significant clinical or laboratory abnormalities that the investigator considers to affect safety assessment, such as: a. uncontrolled diabetes (> 250 mg/dL, or 13.9>mmol/L); b. had high blood pressure and antihypertensive drug treatment under two or unable to descend to the ranges (systolic blood pressure \< 160 mmHg, diastolic pressure \< 100 mmHg); c. peripheral neuropathy (NCI-CTC AE v5.0 grade 2 or above), etc;
  2. Subjects who had a history of congestive heart failure(NCI-CTC AE v5.0 grade 3 or above), uncontrollable or unstable angina or myocardial infarction, cerebrovascular accident or pulmonary embolism in the first 6 months;
  3. Screening of Subjects who have surgery within the first 4 weeks;
  4. Screening for Subjects with arrhythmia requiring treatment or (QTcB) >480ms;
  5. Screening for bacterial, viral, parasitic or fungal infections that require treatment;
  6. Patients which have with a history of congenital or acquired hemorrhagic diseases;(Note:With the exception of hematoma which caused by Ruxolitinib)
  7. Splenectomy Subjects or in the group carried out within three months before the spleen radiation treatment (including internal radiation and external radiation)
  8. Screening , positive or higher than the normal reference range, or positive for HCV antibody;
  9. Women who are planning to become pregnant or who are pregnant or breast- feeding, as well as those who were unable to use effective throughout the trial;Male patients who do not use condoms during the administration and within 2 days (approximately 5 half-lives) after the last administration;
  10. Subjects who have suffered from malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years; Combined with other serious diseases, the researchers believe that patients' safety or compliance may be affected;
  11. With other serious diseases, the researchers think that may affect patient safety or compliance;
  12. Subjects who had used the Jaktinib;
  13. Subjects who have participated in the clinical trials of other new drugs or medical devices within the first 1 months;
  14. Subjects who used the Hematopoietic growth factors within 14 days before Into the group (granulocyte growth factors, or hormone) ;
  15. Subjects who cannot cooperate with or cannot perform MRI or CT scans;
  16. Subjects with or recurrent myelofibrosis:

    refractory of myelofibrosis:After at least 28 days of adequate administration of JAK inhibitors, the spleen palpation was less than 15% smaller than before administration.Or at least 3 months later, the spleen volume on MRI/CT decreased by \<10% compared with that before the administration.

    Recurrence of myelofibrosis: after at least 3 months of taking adequate amount of JAK inhibitor, the spleen was enlarged again after shrinking compared with that before taking the drug, and compared with the minimum value during taking the drug, the spleen volume increased ≥10% on MRI/CT examination or ≥30% on spleen palpation.

  17. Any treatment MF medication (eg hydroxyurea,except ruxolitinib ), any immunomodulation used within 2 weeks prior to enrollment Agent (such as thalidomide), any , ≥ 10 mg/day of prednisone or equivalent biological strength, or Subjects within 6 half-life of the drug, over time Prevail; Subjects who had received Ruxolitinib within 1 week prior to enrolling.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Jaktinib Hydrochloride Tablets 100mg twice a day.

    This is the dose group was given Jaktinib Hydrochloride Tablets 100mg (2 tablets)dose group for twice a day.

    Drug: Jaktinib hydrochloride tablets

  • Experimental
    Jaktinib Hydrochloride Tablets 150mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 150mg (3 tablets)dose group for once a day.

    Drug: Jaktinib hydrochloride tablets

  • Experimental
    Jaktinib Hydrochloride Tablets 100mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 100mg (2 tablets) dose group for once a day

    Drug: Jaktinib hydrochloride tablets

  • Experimental
    Jaktinib Hydrochloride Tablets 200mg once a day

    This is the dose group was given Jaktinib Hydrochloride Tablets 200mg (4 tablets)dose group for once a day.

    Drug: Jaktinib hydrochloride tablets

Interventions

  • Jaktinib hydrochloride tablets 100mg twice dose group,Jaktinib hydrochloride tablets 150mg qd dose group, Jaktinib hydrochloride tablets 200mg qd dose group and Jaktinib hydrochloride tablets 100mg qd dose group

    Also known as: Jaktinib

06

What researchers measure

Primary outcomes

  1. Splenic response rate at Week 24

    Splenic response rate at Week 24 is defined as the proportion of participants achieving a ≥ 35% reduction in spleen volume at Week 24 from baseline

    Time frame: week 24

Secondary outcomes

  1. Objective response rate

    IWG-MRT efficacy criteria

    Time frame: up to 24 weeks

  2. Anemia response rate

    Proportion of anemia response in all of anemia patients

    Time frame: up to 24 weeks

  3. Total symptoms score(TSS) response rate

    TSS response is defined as the proportion of subjects who achieve a ≥ 50% reduction in TSS at the Week 24 compared to baseline

    Time frame: up to 24 weeks

  4. Progression-free survival

    The time from the date of enrollment to the date on which any of the following events occurred:①Spleen volume increased by ≥25% compared to the lowest value recorded during the trial including baseline;②Death from any cause

    Time frame: up to 24 weeks

  5. Leukemia-free survival

    The time elapsed from the date of enrollment to the date of any of the following events:①The first bone marrow smear shows the date of ≥20% of the original cells;②The first peripheral blood smear showed ≥20% of the original cells and the absolute value of the original cells was ≥1×10\^9/L for at least 2 weeks;③Death from any cause。

    Time frame: up to 2 years

  6. Overall survival

    Time elapsed from the date of enrollment to death from any cause

    Time frame: up to 2 years

  7. Adverse event rate

    Vital signs, physical examination, blood routine; severity and incidence of adverse events and adverse reactions (NCI-CTCAE V4.03)

    Time frame: up to 28 weeks

  8. Thrombotic event rate

    Arterial thrombosis:①Coronary heart disease;②Cerebral arterial thrombosis;③Peripheral arterial occlusive disease:Such as mesenteric artery thrombosis and extremity arterial thrombosis。Venous thrombosis:①Thrombophlebitis;②Deep vein thrombosis;③Pulmonary embolism。Microcirculatory thrombosis: ① thrombotic thrombocytopenic purpura; ② hemolytic uremic syndrome; ③ extracorporeal circulation thrombosis; ④other: such as fulminant purple epilepsy and disseminated intravascular coagulation

    Time frame: up to 28 weeks

07

Study locations

1 site
  • The First Affiliated Hospital of Medical School of Zhejiang University
    Hangzhou, Zhejiang 310003, China
08

References and documents

Individual participant data

Plan to share: No — No plan to share date of the trial

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Aug 2022, 30 months.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 30 months is close to that.

Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2019
First posted
Jan 6, 2020
StartActual
Jan 7, 2020
Primary completionActual
Aug 3, 2022
CompletionActual
Aug 3, 2022
Last update
Apr 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04217993
Responsible party
Sponsor
First posted
Jan 6, 2020
Start date
Jan 7, 2020
Primary completion
Aug 3, 2022
Completion
Aug 3, 2022
Last update
Apr 20, 2023

Study contacts

Jie Jin, MD
principal investigator · The First Affiliated Hospital of Medical School of Zhejiang University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion